Abaloparatide

PubChem compound: 145705876

Therapeutic indications

Abaloparatide is indicated for:

Osteoporosis

Population group: women, only adults (18 years old or older)

Treatment of osteoporosis in postmenopausal women at increased risk of fracture.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Abaloparatide is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Severe renal impairment

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Pre-existing hypercalcaemia

Hypercalcemia

Unexplained elevations of serum alkaline phosphatase

Serum alkaline phosphatase raised

Patients with known risks for osteosarcoma

at least one of
Osteosarcoma
Teleradiotherapy procedure

Skeletal malignancies or bone metastases

at least one of
Malignant neoplasm of skeletal system
Secondary malignant neoplasm of bone

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2023: ELADYNOS Solution for injection
Structured Product Labeling (SPL/PLR) 2020: TYMLOS Solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈